AI Built for Pharma: Why Out-of-the-Box Beats Build-From-Scratch
In today’s push to modernize commercial operations, life sciences leaders face a critical decision: build AI solutions in-house or adopt out-of-the-box platforms tailored for pharma.
In this Pharmaceutical Executive panel, powered by ACTO, senior members of the Pharma AI Council discuss the hidden costs, risks, and delays of custom-built approaches. Discover why leading organizations are shifting from consultant-heavy builds to specialized, ready-to-deploy AI tools that seamlessly integrate with systems like Veeva and Salesforce, ensure compliance, and deliver rapid value. Gain practical, data-driven strategies to deploy impactful AI and avoid costly pitfalls in commercial ops, IT, CL&D, and innovation.
Key Learning Objectives
- Understand the pros and cons of building AI in-house vs. buying
- Learn what tips pharma teams to choose out-of-the-box AI solutions
- Explore how built-for-pharma AI can accelerate compliance and value
Executive Summary
AI Built for Pharma: Why Out-of-the-Box Beats Build-from-Scratch
AI in pharma is evolving fast. Industry leaders from Alnylam, Novartis, and ACTO argue that purpose-built AI often beats custom builds—delivering speed, compliance, and impact. ACTO offers a proven, scalable AI platform tailored to life sciences.